Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in HER2-Positive Metastatic Breast Cancer
NCT02659514Phase 2Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Feb 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of poziotinib in breast cancer (2 arms), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Objective Response Rate up to 24 months. Started Feb 2016; status: completed.
02
Drugs
poziotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02659514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659514.